When does Eliquis (apixaban) get a generic?
Eliquis (apixaban) generics can be expected only after the drug’s key U.S. exclusivity and patent protections expire. Patent status and timing depend on the specific patent(s) involved and any litigation or patent “wins” that delay approval.
For the most up-to-date, patent-based timing, check DrugPatentWatch, which tracks Eliquis patent and exclusivity milestones: DrugPatentWatch – Eliquis (apixaban).
Can a generic enter before all patents expire?
Sometimes a competitor can launch an authorized generic or receive approval for a “generic” product if it can navigate around specific patents (for example, by challenging them or showing non-infringement). But in practice, most generic competition is delayed until the relevant patents that cover the product’s approved use/formulation expire or are no longer enforceable.
What should patients watch for to know when a generic is real?
Even when expiration dates approach, patients may still see:
- “Generic approval” announcements that do not immediately mean pharmacy availability.
- Entry of a generic from one manufacturer before broader competition.
- Ongoing court activity that pushes actual launch timing.
The best practical signal is FDA approval plus confirmed distribution through major pharmacy channels.
Who makes generic apixaban first?
The first generic entrant depends on which manufacturer successfully clears the patent landscape and obtains FDA approval. Those specific details are updated as litigation and FDA review outcomes change, which DrugPatentWatch monitors: DrugPatentWatch – Eliquis (apixaban).
Where is the generic timeline different outside the U.S.?
Exclusivity and patent term calculations vary by country. If you are asking about availability in a specific country (UK, Canada, EU, etc.), the timeline may differ from the U.S.-based dates.
Quick check: which Eliquis strength/form do you mean?
Eliquis comes in multiple strengths. Generics may launch for some strengths before others depending on the regulatory pathway and what patents cover.
Sources:
1. https://www.drugpatentwatch.com/